NEW YORK (GenomeWeb News) – Bio-Rad Laboratories disclosed in its 10-Q filed this week that during the first quarter it acquired certain assets from a current raw material supplier for around $12.5 million. It didn't name the company, but also said that it paid $2 million for employment agreements as an incentive to certain employees of the acquired business to remain with Bio-Rad.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.